WILMINGTON, Mass., Feb. 26 /PRNewswire/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its 2009 corporate highlights and year end financial results press release will be issued on Wednesday, March 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Wednesday, March 3rd - 8:30 a.m. E.T.
If calling from the U.S. or Canada use the following toll-free number:
Password - DUSA
For International callers use
A replay of the call will be available approximately 15 minutes following the call
North American callers 877-863-0350
International callers 858-244-1268
The call will be accessible on our web site approximately four hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, for dermatological conditions. Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA is researching the use of Levulan® PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.Back to top
|SOURCE DUSA Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved